The National Institute of Health and Care Excellence (NICE) has published additional new guidance for the month of June 2013. There are two additional clinical guidelines and three new technology appraisals that impact upon primary care.
The Overactive bladder - mirabegron technology appraisal recommends this treatment when antimuscarinics do not work, are not suitable or have side effects that are unacceptable.
The Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban technology appraisal recommends this treatment as a possible treatment for adults with pulmonary embolism and to prevent a further deep vein thrombosis or pulmonary embolism.
The Type 2 diabetes - Dapagliflozin technology appraisal recommends this treatment in dual therapy with metformin only if it is used as described for dipeptidyl peptidase‑4 (DPP‑4) inhibitors in Type 2 diabetes: the management of type 2 diabetes or in combination with insulin with or without other antidiabetic drugs. It is not recommended for use in triple therapy regimen in combination with metformin and a sulfonylurea unless this is part of a clinical trial.
The Ulcerative colitis clinical guideline provides evidence-based advice on the care and treatment of adults, children and young people with a diagnosis of ulcerative colitis.
The Familial breast cancer clinical guideline updates and replaces previous advice. It makes recommendations on genetic testing thresholds, surveillance and risk reduction and treatment strategies for people with a diagnosis of breast cancer and a family history of breast, ovarian or a related cancer.
Action: Clinicians should be aware of this month's additional new guidance and implement any necessary changes to practice.
|« NICE Guidance - June 2013||Drug Safety Update - June 2013 »|